Drugs / Fermagate
last change Oct 2011 re-read 2 minutes ago

Fermagate

Developed for
chronic renal failure syndrome
Investigated by
Ineos Healthcare Limited

Trials 5 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT00436683 Feb 2007 → Jan 2008 chronic renal failure syndrome Ineos Healthcare Limited Completed No outcome recorded
Phase 2 NCT00358722 Jul 2006 → May 2008 chronic renal failure syndrome Ineos Healthcare Limited Terminated No outcome recorded
Phase 2 NCT00317694 Mar 2006 → Jun 2007 chronic renal failure syndrome Ineos Healthcare Limited Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00841126 Jul 2009 → Jul 2011 chronic renal failure syndrome Ineos Healthcare Limited Terminated No outcome recorded
Phase 3 NCT00844662 Jul 2009 → Sep 2011 chronic renal failure syndrome Ineos Healthcare Limited Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Fermagate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00317694
3

NCT00844662

NCT00436683

NCT00358722

Known as Alpharen ChEMBL registry synonym — accepted as the source's own label CHEMBL4297751
Known as Alpharen, magnesium iron hydroxycarbonate Alpharen, magnesium iron hydroxycarbonateNCT00841126
Known as Fermagato ChEMBL registry synonym — accepted as the source's own label CHEMBL4297751
Known as Magnesium iron hydroxycarbonate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00841126
Route Oral “500 mg tablets, administered orally” NCT00841126